Adding bedaquiline or delamanid to background regimen for treatment of multi-drug resistant tuberculosis: a cost-effectiveness analysis

• In: Poster presentation
• At: Seoul (South Korea) (2017)
• Type: Poster
• Poster code: POS-HPS-154
• By: YOU, Joyce (The Chinese University of Hong Kong, School of Pharmacy, Shatin, Hong Kong SAR China)
• Co-author(s): Wai-Ying Yip School of Pharmacy, The Chinese University of Hong Kong, Shatin, Hong Kong
  Joyce You
  
• Abstract:

  Background

  Multi-drug resistant tuberculosis (MDR-TB) is a growing global threat, especially in the Asia region. Background regimens (BRs) for MDR-TB treatment are usually poorly tolerated with moderate success rate. Two anti-TB agents (bedaquiline and delamanid) with improved sputum conversion rates in clinical trials are recently licensed for..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login